Reuters reports the trend among GLP-1 users is prompting calls for tighter rules on supplements sold alongside the drugs.
Recap by typeshit. Post by @Reuters on X.
A pharmacist account flags two separate Class II recalls involving compounded tirzepatide. Tap through for which products are affected and why.
Health authorities in New South Wales issued a warning after a jump in hospitalisations linked to unapproved peptides sold as wellness products.
A University of Iowa chemist found no peptide in a Brooklyn corner-store vial, and another expert flagged at least 13 bacterial colonies that could cause infection.
Cleveland Clinic says early studies give BPC-157 some promise but flags unknown risks, especially when it's bought from gray or black market sellers.
A Facebook user criticizes telehealth marketing of tirzepatide and other GLP-1 services that targets new mothers, calling it predatory. One person's opinion.
The new Medicare program could cut GLP-1 costs by thousands for people on it, though many beneficiaries will not meet the eligibility rules.
Loading…